The outlook for a cure.
Hughes
Virginia
V
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy* / Q000821:virology*; D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D004197:Disease Reservoirs / Q000821:virology; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology*; D019428:HIV Integrase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects / Q000276:immunology; D007249:Inflammation / Q000150:complications / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D055118:Medication Adherence; D019713:Receptors, CCR5 / Q000378:metabolism; D016019:Survival Analysis; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects*; D014775:Virus Activation / Q000187:drug effects / Q000502:physiology; D017735:Virus Latency / Q000187:drug effects / Q000502:physiology; D054320:vif Gene Products, Human Immunodeficiency Virus / Q000037:antagonists & inhibitors / Q000378:metabolism
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D004338:Drug Combinations; D019428:HIV Integrase Inhibitors; D019713:Receptors, CCR5; D054320:vif Gene Products, Human Immunodeficiency Virus